Quantcast
Last updated on April 24, 2014 at 17:35 EDT

Latest Hypnotics Stories

2009-05-21 08:00:00

Safety and Efficacy Study of Zolpidem Tartrate Sublingual Tablet in Treating Middle-of-the-Night Awakening on an As-Needed Basis Evaluation of Ondansetron Augmentation in the Treatment of Obsessive Compulsive Disorder RICHMOND, Calif., May 21 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience,...

2009-05-20 13:27:06

Cognitive behavior therapy and the medication zolpidem taken for six weeks improved sleep in those with persistent insomnia, Canadian researchers found. Charles M. Morin of the Universite Laval in Quebec City and colleagues evaluated the short- and long-term effects of cognitive behavior therapy singly and combined with the medication zolpidem, for persistent insomnia, and compared treatment strategies to optimize long-term outcomes. The trial included 160 adults, who were randomized to...

59a9f5fb4e2ee2c31c1b5b9d0acc1cc91
2009-05-20 12:52:08

New charges in the ongoing lawsuit against British drugmaker AstraZeneca suggest that market executives blocked company scientists from raising concerns that the antipsychotic drug Seroquel caused weight gain and other problems, The Associated Press reported. Plaintiff lawyers say the company researchers were forbidden for years to reveal such concerns because it would harm sales of the drug. They maintain that internal documents released Wednesday back these claims. Patients of the drug for...

2009-05-20 06:59:28

People suffering from insomnia appear to benefit from cognitive behavior therapy (CBT). A recent study found CBT used alone or with the medication zolpidem (Ambien) led to significant improvements in the amount of time it took to fall asleep, the amount of times a person woke up during the night, and how well a person slept during the initial therapy. Researchers at the University Laval in Quebec, Canada, compared the short-term and long-term effects of CBT combined with the zolpidem on...

2009-05-18 11:32:52

Canadian officials warn there's a possibility a small quantity of bottles labeled as containing the medication Rofact may, in fact, contain another drug. Health Canada said some bottles of one lot of Rofact -- an antibiotic manufactured by Valeant Canada that's used to treat tuberculosis and some other infections -- might actually contain the drug clonazepam due to a production error. The affected lot number of Rofact is 8K5467 and the Drug Identification Number is 00343617. Clonazepam is an...

2009-05-08 10:00:00

DETROIT, May 8 /PRNewswire/ -- Henry Ford Hospital is embarking on an unusual study intending to reduce brain damage or death of patients resulting from prolonged seizures before arriving at the hospital. But because the patients are unconscious during the seizure, they will not be able to provide informed consent to participate in the study. The Food and Drug Administration created regulations for research to be performed during emergency conditions without informed consent of the...

2009-04-14 16:31:33

U.S. doctors suggest the depression sometimes linked to a stay in the intensive care unit may be rooted in care issues. The study, published online in Critical Care Medicine, tracked 160 intensive care patients that survived six months after coming to one of 13 Baltimore hospitals for acute lung injury -- a respiratory distress syndrome that despite greatly reduced mortality rates still kills about 40 percent of those affected. The researchers found 26 percent scored above the threshold for...

2009-04-08 18:14:00

WILMINGTON, Del., April 8 /PRNewswire-FirstCall/ -- Today, the U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) conducted a review of the safety and efficacy of supplemental new drug applications (sNDA) for SEROQUEL XR (quetiapine fumarate) extended-release tablets proposed for the treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD). The Advisory Committee concluded: SEROQUEL XR was shown to be effective in MDD as...

2009-04-03 13:15:00

WILMINGTON, Del., April 3 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) is aware that earlier today, the US Food and Drug Administration (FDA) posted to its web site -- and subsequently removed -- briefing documents for the April 8, 2009 Psychopharmacologic Drugs Advisory Committee (PDAC) meeting. The PDAC meeting is scheduled to discuss the safety and efficacy data provided in supplemental new drug applications (sNDA) for SEROQUEL XR(R) (quetiapine fumarate) Extended-Release Tablets...

2009-04-01 10:44:33

Findings suggest that chronic insomnia is a major public health concern, and its diagnosis and appropriate treatment should become the target of public health policy A study in the April 1 issue of the journal SLEEP is the first to demonstrate that chronic insomnia with objectively measured short sleep time is an independent and clinically significant risk factor for hypertension. Results indicate that participants with insomnia and an objectively measured, severely short sleep duration of...